Atea Pharmaceuticals Inc (AVIR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atea Pharmaceuticals Inc (AVIR) has a cash flow conversion efficiency ratio of -0.182x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.08 Million) by net assets ($204.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AVIR stock market capitalisation for the company's overall valuation and market capitalisation.
Atea Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Atea Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Atea Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atea Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore AVIR cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dongwon System
KO:014820
|
0.072x |
|
Geron Co Ltd
SHE:002722
|
-0.018x |
|
Mahindra Logistics Limited
NSE:MAHLOG
|
-0.030x |
|
Focus Minerals Ltd
AU:FML
|
0.372x |
|
Kinko Optical Co Ltd
TW:6209
|
0.009x |
|
Tecnon Fujian Commercial Lighting Co Ltd
SHE:300650
|
-0.166x |
|
Vietnam Construction and Import Export JSC
VN:VCG
|
-0.005x |
|
FM Mattsson Mora Group AB (publ)
ST:FMM-B
|
0.007x |
Annual Cash Flow Conversion Efficiency for Atea Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Atea Pharmaceuticals Inc from 2018 to 2025. View Atea Pharmaceuticals Inc (AVIR) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $275.43 Million | $-132.03 Million | -0.479x | -55.26% |
| 2024-12-31 | $438.87 Million | $-135.50 Million | -0.309x | -100.73% |
| 2023-12-31 | $555.19 Million | $-85.39 Million | -0.154x | +18.56% |
| 2022-12-31 | $640.57 Million | $-120.98 Million | -0.189x | -54.14% |
| 2021-12-31 | $710.08 Million | $-87.00 Million | -0.123x | -122.62% |
| 2020-12-31 | $547.80 Million | $296.73 Million | 0.542x | +109.55% |
| 2019-12-31 | $-49.57 Million | $-12.81 Million | 0.258x | +18.20% |
| 2018-12-31 | $-36.16 Million | $-7.91 Million | 0.219x | -- |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more